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High prevalence of oncogenic MYD88 and CD79B mutations in
diffuse large B-cell lymphomas presenting at immune-privileged
sites
W Kraan1,5, HM Horlings1,5, M van Keimpema1, EJM Schilder-Tol1, MECM Oud1, C Scheepstra2, PM Kluin3, MJ Kersten4, M Spaargaren1
and ST Pals1
Activating mutations in CD79 and MYD88 have recently been found in a subset of diffuse large B-cell lymphoma (DLBCL),
identifying B-cell receptor and MYD88 signalling as potential therapeutic targets for personalized treatment. Here, we report the
prevalence of CD79B and MYD88 mutations and their relation to established clinical, phenotypic and molecular parameters in a
large panel of DLBCLs. We show that these mutations often coexist and demonstrate that their presence is almost mutually
exclusive with translocations of BCL2, BCL6 and cMYC, or Epstein–Bar virus infection. Intriguingly, MYD88mutations were by far most
prevalent in immune-privileged site-associated DLBCL (IP-DLBCL), presenting in central nervous system (75%) or testis (71%) and
relatively uncommon in nodal (17%) and gastrointestinal tract lymphomas (11%). Our results suggest that MYD88 and CD79B
mutations are important drivers of IP-DLBCLs and endow lymphoma-initiating cells with tissue-speciﬁc homing properties or a
growth advantage in these barrier-protected tissues.
Blood Cancer Journal (2013) 3, e139; doi:10.1038/bcj.2013.28; published online 6 September 2013
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous
diagnostic class of lymphomas comprising molecularly distinct
subtypes that differ in gene expression proﬁle, oncogenic
aberrations, clinical presentation and outcome.1,2 A current gene
expression proﬁle-based molecular classiﬁcation of DLBCL
distinguishes two main subtypes: activated B-cell-like (ABC)
lymphoma and germinal centre B-cell-like lymphoma. The
antiapoptotic nuclear factor-kB signalling pathway is
constitutively active in ABC-type DLBCLs as a result of oncogenic
CARD11 mutations and/or of CD79 mutations causing chronic
active B-cell receptor (BCR) signalling enhanced by inactivation of
A20.3–6 In addition, somatically acquired mutations in MYD88, an
adaptor protein that mediates toll-like receptor and interleukin-1
receptor signalling were recently shown to control cell survival in
this lymphoma type by promoting NF-kB and Janus Kinase (JAK)/
Signal transducer and activator of transcription 3 (STAT3) signalling.
These mutations were present in approximately one-third of ABC
DLBCLs. The MYD88 L265P was biologically the most potent mutant
and was unique in its ability to organize a stable signalling complex
containing phosphorylated IRAK1, which was suggested to account
for its high prevalence in lymphomas.7 From a therapeutic
perspective, the above ﬁndings are of great interest as they not
only identify BCR and MYD88 signalling as potential therapeutic
targets but also provide a genetic tool to identify patients that may
beneﬁt from personalized treatment targeting these pathways.
These notions prompted us to explore the prevalence of CD79B
and MYD88 mutations and their relation to established clinical,




The study comprises a panel of 177 DLBCLs diagnosed according to the
WHO (World Health Organization) classiﬁcation. All tissue samples were
obtained during standard diagnostic procedures at the Academic Medical
Center Amsterdam, The Netherlands and afﬁliated hospitals, and the
University Medical Center Groningen, The Netherlands in accordance with
the local institutional board requirements and the Declaration of Helsinki.
Immunohistochemical studies and ﬂuorescence in situ
hybridization
Immunohistochemical stainings were performed on formalin-ﬁxed
parafﬁn-embedded sections with the following antibodies: CD10 (Thermo
Fisher Scientiﬁc, Rockford, IL, USA clone 56C6), MUM1 (clone MUM1p,
DAKO), BCL2 (clone 124, DAKO, Glostrup, Denmark), BCL6 (clone PG-B6p,
DAKO) using a Labvision Autostainer 480S (Thermo Fisher Scientiﬁc).
Expression of the Epstein–Barr virus (EBV) in tumour was determined by
EBV-encoded RNA in situ hybridization probes (Biogenex, Fremont, CA, USA).
Split-ﬂuorescence in situ hybridization for BCL2, BCL6 and cMYC was
performed using probes and a ﬂuorescence in situ hybridization accessory
kit according to the manufacturer’s recommendations (DAKO).
Mutation analysis
DNA was isolated with the QIAamp DNA Micro kit (Qiagen, Venlo,
The Netherlands) according to the manufacturer’s instructions. Screening
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for MYD88 and CD79B mutations was performed with allele-speciﬁc PCR
assays, employing primers that were designed (Table 1) to speciﬁcally
anneal with their 30-terminal nucleotide to either the mutated or wild-type
base. This technique allows reproducible detection of as little as 1%
tumour DNA diluted in wild-type DNA (Supplementary Figure 1). To avoid
aspeciﬁc binding of the primer pairs designed for the mutated to the wild-
type allele, and vice versa, every set was tested at temperatures ranging
from 60 to 64 1C and with different concentrations of MgCl2. To avoid
underdetection of mutations in samples with low tumour load, 100 ng of
DNA was used in each PCR reaction to obtain sufﬁcient DNA originating
from the tumour to detect a potential mutation. In all samples in which a
PCR product was obtained using the mutation-speciﬁc primers, the region
surrounding the mutation was analysed by Sanger sequencing to
verify the presence of a mutation. For cases with low tumour load, PCR
products were cloned before sequencing.
RESULTS
The lymphomas included in this study were diagnosed as DLBCL
according to the WHO criteria. As part of the routine diagnostic
workup, all cases were subclassiﬁed as either ABC- or GC-like by
employing the immunohistochemical algorithm of Hans et al.8
In addition, a systematic molecular characterization consisting of
cMYC, BCL2 and BCL6 translocation analysis employing
ﬂuorescence in situ hybridization, and assessment of EBV status
by EBV-encoded RNA in situ hybridization, were routinely
performed. To detect somatic mutations in MYD88 or CD79B, we
designed a panel of allele-speciﬁc PCRs covering all major
mutation (hot)spots previously reported6,7 (Table 1). This strategy
permits efﬁcient and sensitive detection of mutations using DNA
extracted from parafﬁn-embedded tissue, even in samples with
relatively low tumour load (Supplementary Figure 1). The detected
mutations were veriﬁed by Sanger sequencing.
Of the total group of 177 DLBCL, 43 (24.3%) were found to
contain a MYD88 mutation (Figure 1a). In accordance with the
study of Ngo et al.,7 these mutations were predominantly present
in ABC-type DLBCL (Figure 1b), occurring in 32.5% of ABC DLBCLs
(Figure 1b) as opposed to only 9.5% of GBC DLBCL, and the L265P
mutation was by far the most common mutation. Similarly, CD79B
mutations were also predominantly found in ABC DLBCL (12.2% in
ABC DLBCL vs 0% in germinal centre B-cell-like DLBCL); in more
than half of these tumours, a coexisting MYD88 mutation was
found. Molecular correlation revealed that the presence of MYD88
Table 1. Primer sequences and PCR conditions
Mutation Number Sequence Primer pairs Length Optimal conditions
Temperature MgCl2 concentration
MYD88
L265 WTa 278F 50-GTGCCCATCAGAAGCGACT-30 172bp
64 1C 1.0mM277R 5
0-GGGCCTCAGAACAGTCTTCA-30
Mutb 279F 50-TGCCAGGGGTACTTAGATGG-30 152bp
276R 50-CCTTGTACTTGATGGGGATCG-30
Seqc 279F 50-TGCCAGGGGTACTTAGATGG-30 285bp
277R 50-GGGCCTCAGAACAGTCTTCA-30
S219 WT 286F 50-CTGGCACCTGTGTCTGGTC-30 184bp
61 1C 1.5mM285R 5
0-ATCCCCTGGGAATAGCTTCA-30
Mut 284F 50-ATATGCCTGAGCGTTTCGAT-30 172bp
283R 50-TCGATGAGCTCACTAGCAATAC-30
Seq 284F 50-ATATGCCTGAGCGTTTCGAT-30 316bp
285R 50-ATCCCCTGGGAATAGCTTCA-30
S243 WT 282F 50-GGCATCTCCTCCTAGCTGTG-30 188bp
64 1C 1.0mM281R 5
0-GTCTGGAAGTCACATTCCTTGC-30
Mut 282F 50-GGCATCTCCTCCTAGCTGTG-30 189bp
280R 50-GGTCTGGAAGTCACATTCCTTGT-30
Seq 282F 50-GGCATCTCCTCCTAGCTGTG-30 285bp
291R 50-GGAAGGCTGACAATCCAGAG-30
V217 WT 287F 50-ATATGCCTGAGCGTTTCGAT-30 167bp
62 1C 1.5mM288R 5
0-GAGCTCACTAGCAATAGACCAGAC-30
Mut 287F 50-ATATGCCTGAGCGTTTCGAT-30 167bp
290R 50-GAGCTCACTAGCAATAGACCAGAA-30
Seq 287F 50-ATATGCCTGAGCGTTTCGAT-30 265bp
289R 50-GCACAGCTAGGAGGAGATGC-30
CD79B
Y196 WT 292F 50-CATGGAGGAAGATCACACCT-30 183bp
293R 50-GCAGCGTCACTATGTCCTCA-30
Y196C 296F 50-ATGGAGGAAGATCACACCTG-30 182bp 63 1C 1.0mM
293R 50-GCAGCGTCACTATGTCCTCA-30
Y196D 297F 50-TCTTGCAGAATGCACCTCAC-30 178bp 63 1C 1.0mM
298R 50-CCCCTCTCCTTACCTCGTC-30
Y196F 299F 50-CATGGAGGAAGATCACACCTT-30 183bp 64 1C 1.5mM
293R 50-GCAGCGTCACTATGTCCTCA-30
Y196H 297F 50-TCTTGCAGAATGCACCTCAC-30 176bp 64 1C 1.0mM
294R 50-CCCCTCTCCTTACCTCGTG-30
Y196N 295F 50-CATGGAGGAAGATCACACCA-30 183bp 61 1C 1.5mM
293R 50-GCAGCGTCACTATGTCCTCA-30
seq 297F 50-TCTTGCAGAATGCACCTCAC-30 323bp
293R 50-GCAGCGTCACTATGTCCTCA-30
Abbreviations: Mut, mutated; Seq, sequencing; WT, wild-type. aPrimer pair recognizing the WT allele. bPrimer pair recognizing Mut allele. cPrimer pair used for
Seq.
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and/or CD79B mutations showed hardly any overlap with the
occurrence of cMYC and BCL2 translocations; as expected, these
translocations were largely restricted to the germinal centre
B-cell-like DLBCL subgroup (Figure 1c). Further, EBV infection,
which activates nuclear factor-kB by signals through latent
membrane protein-1 and -2, instigating an ABC phenotype, and
translocation of BCL6, which is present in a subgroup of ABC
DLBCLs, also hardly overlapped with the occurrence of MYD88 and
CD79B mutations (Figure 1c). Taken together, these observations
imply that DLBCL with mutations in MYD88 represent a separate
subgroup of DLBCLs with a distinct molecular pathogenesis.
Consistent with this notion, our study reveals a salient site-speciﬁc
variation in the prevalence of MYD88 mutations: they were
relatively uncommon in ABC DLBCLs arising in lymph nodes (17%)
or gut (11%), whereas tumours arising outside these ‘professional’
lymphoid tissues frequently contained these mutations, either
with or without a coexisting CD79B mutation. Interestingly, these
MYD88 mutations were by far most prevalent in primary
central nervous system (75%) and testicular lymphomas (71%),
which represent the immune-privileged site-associated DLBCLs
(IP-DLBCLs; Figure 2).
DISCUSSION
Our study conﬁrms the previous ﬁnding that MYD88 and CD79B
mutations are predominantly present in ABC-type DLBCL and
often coexist within the same tumour.7 Moreover, it reveals that
these mutations only rarely coexist with translocations of BCL2,
BCL6 and cMYC or with EBV infection, and that they intriguingly
are strongly over-represented in lymphomas presenting outside
‘professional’ lymphoid tissues, particularly in so-called IP-DLBCL
arising in the CNS and testis.
IP-DLBCLs have previously been shown to share a number of
distinctive clinical and biological features. Besides having a
relatively poor prognosis with preferential dissemination to other
immune-privileged sites,9–11 these tumours are predominantly of
the ABC subtype12,13 and show prominent loss of human
leukocyte antigen class I and II expression, often caused by
small interstitial deletions of chromosome 6p21.3.14,15 This is
associated with the downregulation of many immune-associated
genes.12 Our current ﬁnding that most IP-DLBCLs harbour a
MYD88 mutation, while these mutations are uncommon in the
nodal and gastrointestinal tract DLBCLs, supports the concept that



















































Figure 1. Prevalence of MYD88 and CD79B mutations in DLBCL. (a) Percentage of DLBCL with MYD88 and/or CD79B mutations in all DLBCLs
tested (n¼ 177). (b) Percentage of tumours with MYD88 and/or CD79B mutations in ABC-type and germinal centre B-cell (GCB)-type DLBCL.
Prevalence of MYD88 and CD79 mutations in ABC DLBCL was significantly different from that in GC DLBCL (**Po0.01; ***Po0.001 by Fisher’s
exact test). (c) Overlap of MYD88 and CD79B mutations with other recurrent oncogenic events in DLBCL.
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Consistent with this notion, two other studies have recently also
reported a high frequency of MYD88 mutations in primary central
nervous systems.16,17 Conceivably, mutational activation of toll-like
receptor/MYD88 signalling endows lymphoma-initiating cells with a
selective growth advantage at immune-privileged sites. These
tissues are barrier-protected and immunologically silent, and, in
marked contrast to lymph nodes and mucosa-associated lymphoid
tissues, will presumably provide only limited stimulation by toll-like
receptor ligands. The (concomitant) presence of CD79B (or other
BCR pathway) mutations, causing chronic active BCR signalling, may
further promote the selective outgrowth of the tumour cells within
these relatively stimulus poor microenvironments. In view of the
pivotal role of adhesion and chemokine receptors in tissue-speciﬁc
lymphoma dissemination,18,19 dysregulated ‘homing’ of lymphoma
cells carrying oncogenic MYD88 and/or CD79 mutations could
present an alternative mechanism underlying the observed
site-speciﬁc differences in prevalence of these mutations in DLBCL.18
In conclusion, our results suggest that MYD88 mutations, and to a
lesser extent CD79B mutations, are important drivers of lymphoma-
genesis in IP-DLBCLs. Hence, patients with these tumours may
beneﬁt from therapies targeting MYD88 signalling components like
the IRAK4 kinase inhibitors, either alone or in combination with
drugs blocking key mediators of BCR signalling such as Bruton’s
tyrosine kinase.19,20 It will be of interest to explore whether or not
patients with DLBCLs arising in lymph nodes and mucosa-associated
lymphoid tissue and lacking these mutations, nevertheless, also
show evidence of active MYD88 and/or BCR signalling. Such
activation might be triggered by environmental ligands and be
associated with non-oncogene addiction to these pathways.
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Figure 2. Prevalence of mutations in MYD88 and CD79B by tumour
localization. Percentage of ABC DLBCL with MYD88 and/or CD79B
mutations at different anatomical sites. Prevalence of MYD88
mutations in central nervous system (CNS) and testis was
significantly different from that in the lymph node and gastro-
intestinal (GI) tract (***Po0.001 by Fisher’s exact test).
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